Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Recommendation of “Moderate Buy” by Brokerages

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $14.00.

Several research firms have commented on KLRS. Chardan Capital began coverage on Kalaris Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price target for the company. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday.

Kalaris Therapeutics Stock Performance

NASDAQ KLRS opened at $8.67 on Friday. Kalaris Therapeutics has a twelve month low of $2.14 and a twelve month high of $12.90. The stock has a market cap of $162.15 million, a PE ratio of -2.30 and a beta of -0.13. The firm has a 50-day simple moving average of $9.44 and a 200 day simple moving average of $7.18.

Insider Transactions at Kalaris Therapeutics

In other Kalaris Therapeutics news, Director Srinivas Akkaraju acquired 479,847 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average price of $10.42 per share, for a total transaction of $5,000,005.74. Following the purchase, the director owned 1,979,847 shares in the company, valued at $20,630,005.74. This represents a 31.99% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 74.99% of the stock is owned by company insiders.

Institutional Trading of Kalaris Therapeutics

Several institutional investors have recently made changes to their positions in KLRS. Nano Cap New Millennium Growth Fund L P acquired a new position in Kalaris Therapeutics in the fourth quarter worth about $34,000. Barclays PLC acquired a new stake in Kalaris Therapeutics during the fourth quarter valued at approximately $51,000. Johnson Financial Group Inc. acquired a new stake in Kalaris Therapeutics during the third quarter valued at approximately $58,000. XTX Topco Ltd bought a new stake in shares of Kalaris Therapeutics in the 2nd quarter valued at approximately $65,000. Finally, Keel Point LLC bought a new stake in shares of Kalaris Therapeutics in the 4th quarter valued at approximately $86,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.